tiprankstipranks
Satellos Bioscience (MSCLF)
OTHER OTC:MSCLF

Satellos Bioscience (MSCLF) Income Statement

18 Followers

Satellos Bioscience Income Statement

Last quarter (Q3 2023), Satellos Bioscience's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, Satellos Bioscience's net income was C$-3.57K. See Satellos Bioscience’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20
Total Revenue
---C$ 0.00
Cost of Revenue
--C$ 119.92KC$ 48.16K
Gross Profit
--C$ -119.92KC$ -48.16K
Operating Expense
C$ 6.90MC$ 8.43MC$ 4.54MC$ 1.43M
Operating Income
C$ -6.90MC$ -8.43MC$ -4.66MC$ -1.48M
Net Non Operating Interest Income Expense
C$ 270.97KC$ 20.63KC$ 926.21KC$ -12.61K
Other Income Expense
C$ 40.81KC$ -45.39KC$ -9.92MC$ -90.71K
Pretax Income
C$ -10.85MC$ -11.32MC$ -15.51MC$ -1.58M
Tax Provision
C$ 5.62KC$ 5.62K--
Earnings From Equity Interest Net Of Tax
C$ 42.41KC$ 42.41K--
Net Income Common Stockholders
C$ -10.86MC$ -5.07MC$ -15.51MC$ -1.58M
Basic EPS
C$ -0.26C$ -0.32C$ -0.64C$ -0.09
Diluted EPS
C$ -0.26C$ -0.32C$ -0.64C$ -0.09
Basic Average Shares
C$ 155.83MC$ 35.68MC$ 24.08MC$ 17.76M
Diluted Average Shares
C$ 155.83MC$ 35.68MC$ 24.08MC$ 17.76M
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
C$ 6.90M-C$ -4.66MC$ 1.48M
Net Income From Continuing And Discontinued Operation
C$ -10.86MC$ -5.07MC$ -15.51MC$ -1.58M
Normalized Income
C$ -5.09MC$ -5.43MC$ -1.61MC$ -1.57M
Interest Expense
----
EBIT
C$ -10.73MC$ -11.32MC$ -15.51MC$ -1.48M
EBITDA
C$ -10.50MC$ -10.98MC$ -15.34MC$ -1.47M
Currency in CAD

Satellos Bioscience Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis